(Reuters) – Moderna reported preliminary results on Monday for annual sales of its COVID-19 vaccine above the lower end of its own forecast, at $6.7 billion (6.12 billion euros). , while reiterating its objective of returning to sales growth in 2025.
The American laboratory’s action gained 1.5% in pre-market trading on Wall Street.
In November, Moderna said it was aiming for annual revenue at the lower end of its forecast range and expected revenue of at least $6 billion, up from $6 billion to $8 billion previously.
The $6.7 billion in preliminary sales announced by the group includes approximately $600 million in deferred revenue related to Moderna’s efforts under the GAVI global vaccine alliance.
Despite declining demand for vaccines since 2021, Moderna has gained share in the US market compared to rival Pfizer, increasing its share to 48% for the 2023 fall season, up from 37% in 2022.
The group reaffirmed its goal of breaking even in 2026 and said it continues to expect sales of around $4 billion this year for its coronavirus and respiratory syncytial virus (RSV) vaccines.
Regulatory approvals for the RSV vaccine are expected in the first half of this year. Moderna also plans to report late-stage data on its next-generation COVID vaccine and a combined flu and COVID vaccine in 2024.
(Written by Bhanvi Satija in Bangalore, French version Augustin Turpin, edited by Kate Entringer)
©2024 Thomson Reuters, all rights reserved. Reuters content is the intellectual property of Thomson Reuters or its third party content providers. Any copying, republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. Thomson Reuters shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. “Reuters” and the Reuters Logo are trademarks of Thomson Reuters and its affiliated companies.